Laurus Labs Ltd

Dear stakeholders,

I am delighted to present that FY25 has been a transformative year for Laurus Labs, marked by consistent progress, innovation, and a renewed focus on delivering integrated solutions across the life sciences value chain. We have strengthened our position as a trusted global partner, continuously advancing on our strategic priorities while staying deeply committed to quality, sustainability, and long-term value for our stakeholders.

The global life sciences and pharmaceutical industry has continued to evolve, driven by shifting healthcare demands, increasing complexity in drug development, and a greater focus on speed, specialisation, and supply chain resilience. As a result, we have seen increased demand for outsourcing from development to manufacturing services with clients seeking agile, integrated partners who can support them throughout the product lifecycle. This year, we have leveraged our scientific expertise, scalable manufacturing capacity, and commitment to operational excellence, positioning ourselves to meet these demands and remain a leader in the market.

Our ability to rapidly scale production and our extensive portfolio of active pharmaceutical ingredients (APIs) and finished dosage forms (FDFs) and Contract Development and Manufacturing (CDMO) positions us as a key player in the global pharmaceutical supply chain. As a result, we are well-placed to seize opportunities arising from supply chain de-risking driven by geopolitical factors.”

Over the year, we successfully maintained momentum across our business divisions, delivering strong performance through our integrated model. We achieved continued growth in our CDMO business, which became a larger share of our overall portfolio, while also seeing consistent contributions from our generics and API division. We have diversified our revenue streams across customer segments and global regions, including North America, Europe, and the Rest of the World, ensuring that we adapt to market dynamics and reinforce our relationships with key clients.

Our commitment to innovation remains at the core of our strategy. We have proactively invested in R&D capabilities, infrastructure, and technology platforms to enhance our ability to deliver high-quality, cost-effective solutions. We made significant advancements in sustainable and continuous manufacturing, expanded our capacities, and successfully integrated new technologies into our operations. Our efforts to build a comprehensive, scalable R&D platform have positioned us as an efficient, high-quality partner, and we are well-equipped to support customers from early-stage development through to commercial-scale production.

We have maintained our focus on “One Quality for All Markets,” upholding the highest standards of quality, safety, and compliance across all our operations. This year, we continued to make significant strides in our sustainability agenda by enhancing our energy management systems, securing renewable energy partnerships, and applying green technologies in our operations. Our dedication to ESG principles was also recognised through several external awards, reaffirming our position as a responsible corporate citizen.

Our teams have been integral to our success. We have fostered a culture of scientific curiosity, collaboration, and continuous improvement, which has allowed us to drive innovation, deliver excellence, and make a meaningful impact for our customers and communities. Our investment in talent and employee development continues to be a priority, and we are proud of the passion and dedication our teams bring to work every day.

As we look ahead, we remain focused on strengthening our integrated capabilities, scaling our global presence, and deepening our customer partnerships. We will continue to execute on our strategic vision, ensuring that we remain positioned for sustainable long-term growth and create enduring value for all our stakeholders.